AGP Executive Report
Last update: 7 hours agoHIV Research: Taiwan’s TaiMed Biologics reported that 94% of evaluable participants in an early trial maintained viral suppression for 24 weeks on its long-acting, two-antibody HIV regimen, with no confirmed treatment failures. The findings are published in The Lancet HIV and inform an ongoing Phase 2b study. Flu Response: Taiwan will keep expanded access to publicly funded flu antivirals in place through Nov. 30. Infections have declined, but officials cited continued severe cases as a reason not to declare the epidemic over. Medical Exchange: Taipei is hosting the World Congress of Internal Medicine this week. Organizers said they faced no significant political pressure from Beijing during preparations. Population: Taiwan’s population fell for the 34th consecutive month in October, to about 23.2 million. Births rose from September but remained well below the year-earlier figure.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
